Get the Stockscreener App
25.51
1.71%
0.43
Pre-market:
26.99
1.48
+5.80%
Hemab Therapeutics Holdings Inc stock is traded at $25.51, with a volume of 375.45K.
It is up +1.71% in the last 24 hours and down -9.12% over the past month.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
See More
Previous Close:
$25.08
Open:
$24.89
24h Volume:
375.45K
Relative Volume:
3.94
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-31.36
EPS:
-0.8135
Net Cash Flow:
-
1W Performance:
-5.52%
1M Performance:
-9.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.81
$25.96
1-Week Range:
$23.81
$27.95
52-Week Range:
$23.00
$32.00
Hemab Therapeutics Holdings Inc Stock (COAG) Company Profile
Name
Hemab Therapeutics Holdings Inc
Sector
Industry
Phone
45 2138 7627
Address
101 MAIN STREET, CAMBRIDGE
Compare COAG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COAG
Hemab Therapeutics Holdings Inc
|
25.51 | 1.17B | 0 | 0 | 0 | -0.8135 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hemab Therapeutics Holdings Inc Stock (COAG) Latest News
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
Hemab Therapeutics Holdings Inc Stock (COAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hemab Therapeutics Holdings Inc Stock (COAG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 20 '26 |
Buy |
24.94 |
996 |
24,840 |
6,376,968 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 12 '26 |
Buy |
24.90 |
6,387 |
159,036 |
6,372,170 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 11 '26 |
Buy |
24.81 |
39,869 |
989,226 |
6,365,783 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 07 '26 |
Buy |
24.46 |
9,906 |
242,323 |
6,324,431 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
May 08 '26 |
Buy |
24.98 |
1,483 |
37,045 |
6,325,914 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 04 '26 |
Buy |
18.00 |
2,675,000 |
48,150,000 |
6,149,096 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 05 '26 |
Buy |
24.63 |
97,411 |
2,399,546 |
6,246,507 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
May 06 '26 |
Buy |
24.60 |
68,018 |
1,673,399 |
6,314,525 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):